SCHEMBL10166347

SCHEMBL10166347

CC(CN1CCOCC1)Oc1ccc2cnc(N[C@H]3CC[C@H](O)CC3)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.45
MAPK8 P45983 4/20 0.44
MAPK10 P53779 3/20 0.44
MAPK9 P45984 2/20 0.44
CDK2 P24941 4/20 0.41
CCNA2 P20248 3/20 0.41
CDK7 P50613 3/20 0.41
CCNH P51946 3/20 0.41
MNAT1 P51948 3/20 0.41
CCNK O75909 2/20 0.41
CDK12 Q9NYV4 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MERTK Q12866 8/20 0.41
TYRO3 Q06418 7/20 0.41
GAS6 Q14393 6/20 0.41
FLT3 P36888 5/20 0.41
AXL P30530 3/20 0.41
IRAK4 Q9NWZ3 1/20 0.40
CCNE1 P24864 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559773 1.00 MAPK1 (0.45) MAPK1MAPK8MAPK10MAPK9CDK2
SCHEMBL559774 1.00 MAPK1 (0.45) MAPK1MAPK8MAPK10MAPK9CDK2
SCHEMBL10166375 0.87 MAPK1 (0.42) MAPK1MAPK8MAPK10MAPK9CDK2
SCHEMBL559365 0.87 MAPK1 (0.42) MAPK1MAPK8MAPK10MAPK9CDK2
SCHEMBL559366 0.87 MAPK1 (0.42) MAPK1MAPK8MAPK10MAPK9CDK2
SCHEMBL559235 0.84 SYK (0.46) MAPK1MAPK8MAPK10MERTKTYRO3
SCHEMBL559234 0.84 SYK (0.46) MAPK1MAPK8MAPK10MERTKTYRO3
SCHEMBL10166348 0.81 MAPK8 (0.45) MAPK1MAPK8MAPK10MAPK9CDK2
SCHEMBL559284 0.81 MAPK8 (0.45) MAPK1MAPK8MAPK10MAPK9CDK2
SCHEMBL559285 0.81 MAPK8 (0.45) MAPK1MAPK8MAPK10MAPK9CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2012-02-09 US disclosed
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2012-02-09 US disclosed
US-7998978-B2 Substituted 2-amino-fused heterocyclic compounds PFIZER INC. (US) 2011-08-16 US disclosed
US-7998978-B2 Substituted 2-amino-fused heterocyclic compounds PFIZER INC. (US) 2011-08-16 US disclosed
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-03-04 US disclosed
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS PFIZER PRODUCTS INC. (US) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035194-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS MAPK1, SLC5A1, ATF1 MAPK1 1/4885MAPK8 20/4885MAPK10 32/4885
US-20100056506-A1 SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS MAPK1, SLC5A1, ATF1 MAPK1 1/4885MAPK8 20/4885MAPK10 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.